Analysts Issue Research Notes On Royalty Pharma plc (RPRX)

0
8
MDVL Stock
MDVL Stock

Royalty Pharma plc (NASDAQ:RPRX) finished Thursday with a subtraction of -$0.46 to close at $40.60, a downside of -1.12 percent. An average of 1,927,944 shares of common stock have been traded in the last five days. There was a fall of -$1.48 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 1,796,086 shares traded, while the 50-day average volume stands at 1,884,452.

RPRX stock has decreased by -5.50% in the last month. The company shares reached their 1-month lowest point of $40.36 on 09/22/22. With the stock rallying to its 52-week high on 04/14/22, shares of the company touched a low of $34.86 and a high of $44.75 in 52 weeks. It has reached a new high 6 times so far this year and achieved 3.04% or $0.62 in price. In spite of this, the price is down -9.27% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Insider Transactions

2 days have passed since Royalty Pharma plc (RPRX) last reported insider trading activity. Giuliani Mario Germano, who is Director, most recently acquired $125,697 shares at $41.25 per share on Sep 21. In this transaction, the insider spent $5,185,378. Director, Giuliani Mario Germano, disposed of 398,145 shares at a price of $41.02 on Sep 20. The insider now owns more than $16,331,175 worth of shares. Prior to that, 10% Owner GG 1978 SICAF SIF S.A. – GG St went on to Sale 267,815 shares at $41.02 each on Sep 20. An amount of $10,985,798 was transacted.

Valuation Metrics

Royalty Pharma plc (RPRX) has a trailing price-to-earnings (P/E) ratio of 38.27. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 11.09, the price-to-book (PB) ratio at 2.97, and the price-to-cash flow ratio at 250634.35.

The company has a payout ratio of 67.10%. The company’s most recent quarterly dividend payment was $0.19 a share, without any change from last year. Its latest increase dividend $0.02 reported on Thursday January 6 2022.

Financial Health

The quick ratio of Royalty Pharma plc for the three months ended June 29 was 19.20, and the current ratio was 19.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.18 and a total debt to equity ratio of 1.18 for the quarter ending June 29. Its gross profit as reported stood at $858.75 million compared to revenue of $2.29 billion.

Earnings Surprise

For the three-month period that ended June 29, Royalty Pharma plc had $654.1 million in cash and short-term investments compared to $7.11 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $304.5 million in the quarter, while revenues of $51.76 million were shrunk -44.76%. The analyst consensus anticipated Royalty Pharma plc’s latest quarter earnings to come in at $0.78 per share, but it turned out to be $0.79, a 1.30% surprise. For the quarter, EBITDA amounted to $383.13 million. Shareholders own equity worth $607.22 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Royalty Pharma plc (RPRX) price momentum. RSI 9-day as of the close on 22 September was 27.17%, suggesting the stock is oversold, with historical volatility in this time frame at 11.74%.

As of today, RPRX’s price is $40.98 -3.53% or -$1.48 from its 5-day moving average. RPRX is currently trading -7.31% lower than its 20-day SMA and -4.44% lower than its 100-day SMA. However, the stock’s current price level is -6.28% below the SMA50 and +4.98% above the SMA200.

The stochastic %K and %D were 7.42% and 9.04%, respectively, and the average true range (ATR) was 0.85. With the 14-day stochastic at 2.87% and the average true range at 0.84, the RSI (14) stands at 32.29%. The stock has reached -0.82 on the 9-day MACD Oscillator while the 14-day reading was at -1.32.

Analyst Ratings

The consensus rating for Royalty Pharma plc (RPRX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell RPRX, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 9 others rate it as a “buy”.

What is RPRX’s price target for the next 12 months?

Analysts predict a range of price targets between $49.40 and $60.00, with a median target of $53.00. Taking a look at these predictions, the average price target given by analysts for Royalty Pharma plc (RPRX) stock is $53.64.

LEAVE A REPLY

Please enter your comment!
Please enter your name here